 |
|
Safety and Tolerability of Intermittent Rifampin/Pyrazinamide for the Treatment of Latent Tuberculosis Infection in Prisoners
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Two months of treatment with
rifampin and pyrazinamide is effective in preventing tuberculosis (TB) in
tuberculin-positive, human immunodeficiency virus (HIV)-seropositive individuals.1-2 Recent reports, however, have
raised concerns about the safety of rifampin and pyrazinamide for latent TB
infection in HIV-seronegative individuals, although toxicity incidence is
not known.3 The reported adverse events
have occurred with use of a daily regimen. We studied the outcomes of a twice-weekly
regimen of these medications to treat latent TB in 600 prison inmates in Maryland.
Methods
From December 1, 1999 through June 30, 2001, inmates of the Maryland
Department of Public Safety and Correctional Services (DPSCS) who had a reactive
tuberculin skin test (defined as  5 mm), no radiographic evidence of active
TB, and normal aminotransferase levels, were given rifampin and pyrazinamide
twice weekly for 8 weeks. Rifampin dose was 450 mg for inmates weighing less
than 50 kg and 600 mg for . . . [Full Text of this Article]
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy.
Saukkonen et al.
Am. J. Respir. Crit. Care Med. 2006;174:935-952.
ABSTRACT
| FULL TEXT
Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection
Blumberg et al.
JAMA 2005;293:2776-2784.
ABSTRACT
| FULL TEXT
Tuberculosis Chemotherapy: Still a Double-edged Sword
Chaisson
Am. J. Respir. Crit. Care Med. 2003;167:1461-1462.
FULL TEXT
Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis
Stout et al.
Am. J. Respir. Crit. Care Med. 2003;167:824-827.
ABSTRACT
| FULL TEXT
Global Drug-Resistance Patterns and the Management of Latent Tuberculosis Infection in Immigrants to the United States
Khan et al.
NEJM 2002;347:1850-1859.
ABSTRACT
| FULL TEXT
|
